Monday - November 3, 2025
Johnson & Johnson Announces First Head-to-head Study Comparing IMAAVY With an Alternative FcRn Blocker in Generalized Myasthenia Gravis at AANEM Annual Meeting
October 30, 2025
RARITAN, New Jersey, Oct. 30 -- Johnson and Johnson Innovative Medicine issued the following news release on Oct. 29, 2025:

* * *

Johnson & Johnson announces first head-to-head study comparing IMAAVY with an alternative FcRn blocker in generalized myasthenia gravis (gMG) at AANEM Annual Meeting

The EPIC study will evaluate treatment with IMAAVY versus efgartigimod in adults with gMG and will include a treatment-switch arm

The Company also a . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products